IceCure's Advanced Multiprobe Cryoablation Technology Receives Patent Approval in Japan
November 25, 2024 - 22:01
IceCure Medical Ltd. has announced that its next-generation multiprobe cryoablation technology has received a Notice of Allowance from Japan's Patent Office. This significant development marks a key milestone for the company's innovative approach to minimally invasive medical procedures.
The multiprobe cryoablation technology is designed to enhance the effectiveness and efficiency of cryoablation treatments, which are used to destroy abnormal tissues through extreme cold. This advancement is expected to provide physicians with improved tools for treating various medical conditions, potentially leading to better patient outcomes.
The approval from Japan's Patent Office underscores the technological advancements that IceCure is bringing to the field of cryoablation, positioning the company for growth in the competitive medical technology market.
MORE NEWS
July 7, 2026 - 04:02
EQT to acquire parking technology firm OrikanEQT has announced its acquisition of Orikan, a company known for providing parking and compliance technology. The deal is aimed at accelerating growth, advancing artificial intelligence...
July 6, 2026 - 19:57
Toward a future that preserves benefits of neurotechnology for allA researcher from the Harvard-MIT Health Science and Technology program has won a major prize for her vision of how brain-computer interfaces could shape society. Rachel Sava, a PhD candidate, took...
July 6, 2026 - 11:42
AI Job Disruption Has Come for Ireland's Technology SectorIreland`s technology sector, which enjoyed a prolonged jobs boom fueled by a wave of US multinationals setting up European headquarters, is now facing a sharp reversal. The very force that helped...
July 5, 2026 - 20:48
Market Dispersion Rises as Technology Leadership FadesInvestors are watching a shift in market dynamics as the once-dominant technology sector shows signs of losing its grip on leadership. Market dispersion, a measure of how widely stock returns vary...